Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma

Seminars in Radiation Oncology

Volumn 26, Issue 2, 2016, Pages 112-119

  Quan, Kimmen ^a   Xu, Karen M ^a   Zhang, Yongqian ^a   Clump, David A ^a   Flickinger, John C ^a   Lalonde, Ron ^a   Burton, Steven A ^a   Heron, Dwight E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; BONE NECROSIS; BRAIN NECROSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CYBERKNIFE; DERMATITIS; DIGESTIVE SYSTEM FISTULA; DYSGEUSIA; DYSPHAGIA; DYSPHONIA; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERPIGMENTATION; LINEAR ACCELERATOR; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; ODYNOPHAGIA; OVERALL SURVIVAL; PAIN; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION INJURY; RASH; RE-IRRADIATION; RECURRENCE FREE SURVIVAL; REVIEW; SKIN FIBROSIS; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; STOMATITIS; TISSUE NECROSIS; TUMOR RECURRENCE; TUMOR VOLUME; VERY ELDERLY; XEROSTOMIA; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIATION INJURIES; RADIATION RESPONSE; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; RETREATMENT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETREATMENT; TREATMENT OUTCOME;

EID: 84960807899     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.11.007     Document Type: Review

References (29)

1. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
2. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-1944.
3. Fakhry C., Zhang Q., Nguyen-Tan P.F., et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014, 32:3365-3373.
4. Dakubo G.D., Jakupciak J.P., Birch-Machin M.A., et al. Clinical implications and utility of field cancerization. Cancer Cell Int 2007, 7:2.
5. Cooper J.S., Pajak T.F., Rubin P., et al. Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989, 17:449-456.
6. Coatesworth A.P., Tsikoudas A., MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol 2002, 116:269-271.
7. Clavel M., Vermorken J.B., Cognetti F., et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994, 5:521-526.
8. Argiris A., Li Y., Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004, 101:2222-2229.
9. Sulman E.P., Schwartz D.L., Le T.T., et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009, 73:399-409.
10. Salama J.K., Vokes E.E., Chmura S.J., et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006, 64:382-391.
11. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
12. Heron D.E., Rwigema J.C., Gibson M.K., et al. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: A single institution matched case-control study. Am J Clin Oncol 2011, 34:165-172.
13. John A., Vargo R.L.F., Ohr James, et al. Clump: A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2015, 91:480-488.
14. Heron D.E., Ferris R.L., Karamouzis M., et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: Results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009, 75:1493-1500.
15. Comet B., Kramar A., Faivre-Pierret M., et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys 2012, 84:203-209.
16. Iwata H., Tatewaki K., Inoue M., et al. Salvage stereotactic reirradiation using the CyberKnife for the local recurrence of nasal or paranasal carcinoma. Radiother Oncol 2012, 104:355-360.
17. Lartigau E.F., Tresch E., Thariat J., et al. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol 2013, 109:281-285.
18. Vargo J.A., Ferris R.L., Ohr J., et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2015, 91:480-488.
19. Roh K.W., Jang J.S., Kim M.S., et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 74:1348-1355.
20. Unger K.R., Lominska C.E., Deeken J.F., et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010, 77:1411-1419.
21. Cengiz M., Ozyigit G., Yazici G., et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011, 81:104-109.
22. Vargo J.A., Heron D.E., Ferris R.L., et al. Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: Implications of treatment duration and tumor volume. Head Neck 2014, 36:1349-1355.
23. Kress M.A., Sen N., Unger K.R., et al. Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series. Head Neck 2015, 37(10):1403-1409.
24. Leung L.H., Wong W.K., Cheng A.C., et al. A new approach to computing normal tissue complication probability of an intensity-modulated radiotherapy treatment with stereotactic radiotherapy boost of nasopharyngeal carcinoma: A case study. Med Dosim 2011, 36:138-144.
25. Nelson J.W., Yoo D.S., Sampson J.H., et al. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys 2009, 73:1369-1375.
26. Ma L., Kirby N., Korol R., et al. Assessing small-volume spinal cord dose for repeat spinal stereotactic body radiotherapy treatments. Phys Med Biol 2012, 57:7843-7851.
27. Rwigema J.C., Heron D.E., Ferris R.L., et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol 2011, 34:372-379.
28. Okunieff P., Morgan D., Niemierko A., et al. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys 1995, 32:1227-1237.
29. Moiseenko V., Song W.Y., Mell L.K., et al. A comparison of dose-response characteristics of four NTCP models using outcomes of radiation-induced optic neuropathy and retinopathy. Radiat Oncol 2011, 6:61.